Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

51.8K
Overview
51.8K
Cancer Vaccines01:30

Cancer Vaccines

1.1K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and validation of a Relapsing Polychondritis disease-specific Quality of Life instrument (ERN ReCONNET RP-QoL).

Rheumatology (Oxford, England)·2026
Same author

Association between cumulative glucocorticoid exposure and epicardial adipose tissue volume in systemic lupus erythematosus.

EULAR rheumatology open·2026
Same author

Ring-like late gadolinium enhancement pattern in antimalarial-induced cardiomyopathy.

European heart journal. Case reports·2026
Same author

Affinity-matured B cell responses neutralizing type-I interferons underlie severe viral infections.

Cell·2026
Same author

Serum lipidomic and metabolomic signatures link epicardial adipose tissue to cardiovascular diseases in SLE: a post-hoc analysis.

Lupus science & medicine·2026
Same author

Severe thrombocytopenia in antiphospholipid syndrome: a retrospective study of 432 patients.

RMD open·2026
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Related Experiment Video

Updated: Feb 9, 2026

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
05:39

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

684

Lupus and vaccinations.

Alexis Mathian1,2, Micheline Pha1, Zahir Amoura1,2

  • 1Department of Internal Medicine 2, French National Reference Center for Systemic Lupus Erythematosus and Antiphospholipid Antibody Syndrome, Institut E3M, Groupement Hospitalier Pitié Salpêtrière, Assistance Publique Hôpitaux de Paris (AP-HP).

Current Opinion in Rheumatology
|June 12, 2018
PubMed
Summary
This summary is machine-generated.

Vaccinations for systemic lupus erythematosus (SLE) patients are safe but less immunogenic. Improving vaccine coverage requires educating patients and physicians on their safety, efficacy, and benefits for SLE management.

More Related Videos

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.8K
Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

24.0K

Related Experiment Videos

Last Updated: Feb 9, 2026

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
05:39

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

684
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.8K
Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

24.0K

Area of Science:

  • Immunology
  • Rheumatology
  • Vaccinology

Background:

  • Systemic lupus erythematosus (SLE) is an autoimmune disease impacting multiple organs.
  • Patients with SLE are at increased risk of infections.
  • Vaccinations are crucial for preventing infections in immunocompromised individuals.

Purpose of the Study:

  • To review current data on vaccine efficacy and safety in SLE patients.
  • To focus on pneumococcal, influenza, herpes zoster, and human papillomavirus (HPV) vaccines.
  • To assess the immunogenicity and adverse effects of vaccinations in SLE.

Main Methods:

  • Review of recent studies and meta-analyses on vaccinations in SLE.
  • Analysis of data on pneumococcal polysaccharide (PPS23) and conjugate vaccines.
  • Evaluation of influenza vaccine impact on morbidity and mortality.
  • Assessment of quadrivalent HPV vaccine safety and immunogenicity.

Main Results:

  • Pneumococcal vaccine response in SLE patients is often inadequate (<40%).
  • Sequential pneumococcal vaccination strategies did not improve immunogenicity over PPS23 alone.
  • Annual influenza vaccination reduces morbidity and mortality in SLE with no significant adverse effects.
  • Quadrivalent HPV vaccine is safe and highly immunogenic in SLE patients.
  • Both pneumococcal and influenza vaccines exhibit lower immunogenicity in SLE.

Conclusions:

  • Vaccines for SLE patients are generally safe but show reduced immunogenicity.
  • Enhanced immunization coverage in SLE necessitates improved patient and physician awareness.
  • Information dissemination on vaccine safety, efficacy, and benefits is critical for SLE management.